Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice.


Journal

Chemotherapy
ISSN: 1421-9794
Titre abrégé: Chemotherapy
Pays: Switzerland
ID NLM: 0144731

Informations de publication

Date de publication:
2020
Historique:
received: 19 11 2019
accepted: 08 06 2020
pubmed: 11 8 2020
medline: 4 5 2021
entrez: 11 8 2020
Statut: ppublish

Résumé

The effects of chemotherapy are known to depend on the time of administration. Circadian rhythms are disturbed in tumors and in tumor bearers. Agents involved in controlling the circadian rhythms (chronobiotics) potentially can modify the outcomes of chemotherapeutics administered at different times of the day. Pineal hormone melatonin (MT) is a prototypic chronobiotic. The aim of the study was to investigate if MT can affect efficacy or toxicity of chemotherapy drugs administered at the extreme time points of the working day of hospital personnel. Cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) and adriamycin and docetaxel (AT) cytotoxic drug combinations were administered on day 0 at 11:00 a.m. or at 5:00 p.m. (UTC+03:00) to 6-month-old female HER2/neu transgenic FVB/N mice bearing mammary adenocarcinomas. Some mice were additionally provided with MT in drinking water (20 mg/L) at night 1 week before or 3 weeks after treatment or during both periods. Tumor node sizes, body weight, and blood cell counts were determined right before treatment and on days 2, 7, 14, and 21. Significant decrease in the mean tumor node volume was found by days 14 and 21 upon all CAF and AT treatment schedules, except in animals treated with AT at 5:00 p.m. without supplementation with MT. In the latter case, mean tumor node volume on day 21 was the same as in the control. Supplementation of AT administered at 5:00 p.m. with MT improved the tumor response. CAF and AT regimens supplemented with MT also augmented the number of tumor nodes that did not increase by more than 20% by day 21 as compared to CAF or AT alone, respectively. This effect was significant in groups treated with AT at 5:00 p.m. and consistent upon other schedules. On day 7, leukopenia and anemia were registered in groups treated with CAF regimen; however, blood cell counts normalized by day 14. Both CAF and AT were associated with drop in the body weight registered on day 7. Supplementation with MT did not affect changes of the body weight and blood counts. MT supplementation to cytotoxic drugs can improve antitumor response, especially if it is blunted because of an inappropriate time of administration.

Identifiants

pubmed: 32772021
pii: 000509238
doi: 10.1159/000509238
doi:

Substances chimiques

Antineoplastic Agents 0
Docetaxel 15H5577CQD
Doxorubicin 80168379AG
Cyclophosphamide 8N3DW7272P
Receptor, ErbB-2 EC 2.7.10.1
Melatonin JL5DK93RCL
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

42-50

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Andrey V Panchenko (AV)

Department of Carcinogenesis and Oncogerontology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation, ando.pan@gmail.com.

Margarita L Tyndyk (ML)

Department of Carcinogenesis and Oncogerontology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation.

Mikhail A Maydin (MA)

Department of Carcinogenesis and Oncogerontology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation.

Irina A Baldueva (IA)

Department of Oncoimmunology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation.

Anna S Artemyeva (AS)

Department of Pathomorphology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation.

Stepan S Kruglov (SS)

Department of Carcinogenesis and Oncogerontology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation.

Galina S Kireeva (GS)

Department of Carcinogenesis and Oncogerontology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation.

Alexey G Golubev (AG)

Department of Carcinogenesis and Oncogerontology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation.

Alexey M Belyaev (AM)

Department of Carcinogenesis and Oncogerontology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation.

Vladimir N Anisimov (VN)

Department of Carcinogenesis and Oncogerontology, N.N. Petrov National Medical Research Center of Oncology of the Russian Ministry of Health, St. Petersburg, Russian Federation.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH